Stage-specific pharmacodynamic chloroquine and pyronaridine action on artemisinin ring-stage resistant Kelch C580Y mutation Plasmodium falciparum correlates to hemozoin inhibition process
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01208-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Abeer Sayeed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Plasmodium falciparum, Chloroquine, Antimalarials, Hemeproteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Bloomberg Family Foundation (The Bloomberg Family Foundation), JHSPH | Johns Hopkins Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health.
Abstract (Originalsprache)
The antimalarial quinolines pyronaridine and chloroquine both inhibit hemozoin crystallization, predominately produced by Plasmodium falciparum intra-erythrocytic trophozoite stage parasites. Pyronaridine extends activity to ring-stage chloroquine-sensitive parasites, in contrast to chloroquine. Here, we investigated chloroquine and pyronaridine hemozoin inhibition type correlated to stage-specific activity on chloroquine-resistant ring-stage artemisinin sensitive and resistant P. falciparum CamWT and CamWT-C580Y parasites. Pyronaridine (2.8 μM) is tenfold more potent at beta-hematin nucleation than chloroquine (40 μM). Both pyronaridine and chloroquine (0.2 and 0.7 μM, respectively) had similar sub-μM inhibition of beta-hematin extension. P. falciparum CamWT-C580Y parasites produce smaller width hemozoin crystals which extend less than isogenic CamWT hemozoin. Stage-specific pulse dose pyronaridine and chloroquine on CamWT-C580Y or CamWT isogenic parasites observed 3- to 4-fold higher pyronaridine IC 50 s compared to 10- to 15-fold higher chloroquine on most CamWT-C580Y to CamWT stages. These findings collectively show that hemozoin nucleation inhibition widens stage-specific pyronaridine activity on P. falciparum drug-resistant parasites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, USA.
- Department of Chemistry, University of Houston, Houston, Texas, USA.
ORCID-Profile: David J Sullivan
Förderung
- NIAID NIH HHS
- Bloomberg Family Foundation (The Bloomberg Family Foundation)
- JHSPH | Johns Hopkins Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health
- HHS | NIH | National Institute of Allergy and Infectious Diseases
Zitieren
APA
Sayeed, A., Atkinson, R., Vekilov, P. G., Rimer, J. D., & Sullivan, D. J. (2025). Stage-specific pharmacodynamic chloroquine and pyronaridine action on artemisinin ring-stage resistant Kelch C580Y mutation Plasmodium falciparum correlates to hemozoin inhibition process. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01208-24
Vancouver
Sayeed A, Atkinson R, Vekilov PG, Rimer JD, Sullivan DJ. Stage-specific pharmacodynamic chloroquine and pyronaridine action on artemisinin ring-stage resistant Kelch C580Y mutation Plasmodium falciparum correlates to hemozoin inhibition process. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01208-24
BibTeX
@article{Sayeed2025,
author = {Sayeed, Abeer and Atkinson, Revie and Vekilov, Peter G and Rimer, Jeffrey D and Sullivan, David J},
title = {Stage-specific pharmacodynamic chloroquine and pyronaridine action on artemisinin ring-stage resistant Kelch C580Y mutation Plasmodium falciparum correlates to hemozoin inhibition process},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01208-24}
}
EUVIMED